Clinical Outcomes Research
Our unique position in the outpatient infusion management setting, in collaboration with our physician partners, gives us unprecedented access to the highest quality real-world clinical data.
Our data warehouse is the largest in the outpatient infusion industry
Our data sets go way beyond simple claims data and provide evidence-based research in areas such as drug utilization, clinical outcomes and disease response, safety, health economic impacts, and persistence. The strength of our data allows us to collaborate with manufacturers and physicians to study novel therapies, compare treatment sites, and other cutting-edge research.
Clinical Outcomes
Cost Savings & Lower Resource Utilization
New Therapies and Programs
Persistance
Special Populations
Here is an example of one of our class-leading studies enabled by our data:
Click image to view full size
Infection Incidence and Utilization of Antimicrobials in Physician Office Infusion Centers (POICs)
Lucinda J. Van Anglen, PharmD - Healix Infusion Therapy, Sugar Land, TX Thomas C. Hardin, PharmD - Healix Infusion Therapy, Sugar Land, TX Claudia P. Schroeder, PharmD, PhD - Healix Infusion Therapy, Sugar Land, TX View Poster
Therapeutic Drug Monitoring of Biologics in patients with Inflammatory Bowel Disease: A Real-World Experience
Authors: Chris Fourment, MD - Texas Digestive Disease Consultants, PA, Southlake, TX Timothy E. Ritter, MD, - Texas Digestive Disease Consultants, PA, Southlake, TX Bitaal Sadiq, BS - Texas Digestive Disease Consultants, PA, Southlake, TX Claudia P. Schroeder,...
Mandated Payor Switching with Infliximab (IFX) Bioimilars
Authors: Harry E. Sarles, MD, FACG - DHAT Research Institute, Richardson, TX Lucinda J. Van Anglen, PharmD - Healix Infusion Therapy, Sugar Land, TX Thomas C. Hardin, PharmD - Healix Infusion Therapy, Sugar Land, TX View...
Healthcare Resource Utilization in Inflammatory Bowel Disease Patients: A 2-Year Analysis
Authors: Harry E. Sarles, MD, FACG - DHAT Research Institute, Richardson, TX Lucinda J. Van Anglen, PharmD - Healix Infusion Therapy, Sugar Land, TX Thomas C. Hardin, PharmD - Healix Infusion Therapy, Sugar Land, TX Claudia P. Schroeder, PharmD, PhD - Healix...
Infection Incidence and Utilization of Antimicrobials in Physician Office Infusion Centers (POICs)
Lucinda J. Van Anglen, PharmD - Healix Infusion Therapy, Sugar Land, TX Thomas C. Hardin, PharmD - Healix Infusion Therapy, Sugar Land, TX Claudia P. Schroeder, PharmD, PhD - Healix Infusion Therapy, Sugar Land, TX View...
Real World Experience of Bezlotoxumab for Prevention of Recurrent C. Difficile Infection: A Single-Arm Multicenter Pilot Study in Office Infusion Centers
Timothy E. Ritter - Texas Digestive Disease Consultants, Southlake, TX Richard L. Hengel - Atlanta ID Group, Atlanta, GA; Piedmont Healthcare, Atlanta, GA Curtis J. Fitzsimmons - Plaza Infectious Disease, Kansas City, MO; University of Missouri-Kansas City, MO...
Real World Evaluation of Prolonged Clinical Response with Vedolizumab in Crohn’s Disease and Ulcerative Colitis patients Treated in a Private Practice Setting
Authors: Timothy E. Ritter, MD - Texas Digestive Disease Consultants, PLLC, Southlake, TX Christopher Fourment, MD - Texas Digestive Disease Consultants, PLLC, Southlake, TX Lucinda J. Van Anglen, PharmD - Healix Infusion Therapy, Inc, Sugar Land, TX Tracy C....
Long-Term Safety Analysis of Vedolizumab for Treatment of Crohn’s Disease and Ulcerative Colitis
Authors: Timothy E. Ritter, MD - Texas Digestive Disease Consultants, PA, Southlake, TX Chris Fourment, MD - Texas Digestive Disease Consultants, PA, Southlake, TX; Lucinda J. Van Anglen, PharmD - Healix Infusion Therapy, Inc., Sugar Land, TX Thomas C. Hardin,...
Can Vedolizumab Non-Responders Be Treated Successfully with Another Biologic Agent?
Authors: Timothy E. Ritter, MD - Texas Digestive Disease Consultants, PA, Southlake, TX Chris Fourment, MD - Texas Digestive Disease Consultants, PA, Southlake, TX; Lucinda J. Van Anglen, PharmD - Healix Infusion Therapy, Inc., Sugar Land, TX Thomas C. Hardin,...
Successful Establishment of an Antimicrobial Stewardship Program (ASP) for Outpatient Parenteral Antimicrobial Therapy (OPAT)
Authors: Ramesh V. Nathan, MD - Mazur, Statner, Dutta, Nathan, PC, Thousand Oaks, CA John S. Adams, MD - Knoxville Infectious Disease Consultants, PC, Knoxville, TN Robin H. Dretler, MD - Infectious Disease Specialists of Atlanta, PC, Decatur, GA Quyen Luu, MD -...
Clinical and Economic Outcomes of Outpatient Parenteral Antimicrobial Therapy (OPAT) Among Indigent Patients: A Retrospective Multicenter Analysis
Authors: Brian S. Metzger, MD, MPH - Austin Infectious Disease Consultants, Austin, TX Richard M. Mandel, MD - Southern Arizona Infectious Disease Specialists, Tucson, AZ Claudia P. Schroeder, PharmD, PhD - Healix Infusion Therapy, Inc., Sugar Land, TX Lucinda J....
Outpatient Treatment of Infective Endocarditis (IE) at Physician Office Infusion Centers (POICs): A 2-Year Analysis of Clinical and Economic Outcomes
Authors: Brian S. Metzger, MD, MPH - Austin Infectious Disease Consultants, Austin, TX Richard M. Mandel, MD, FIDSA - Southern Arizona Infectious Disease Specialists, PLC, Tucson, AZ Jorge R. Bernett, MD - Infectious Disease Doctors Medical Group, Walnut Creek, CA...
Ceftolozane/Tazobactam: Outpatient Treatment of Gram-Negative Infections at Physician Office Infusion Centers (POICs)
Authors: Ramesh V. Nathan, MD, FIDSA - Mazur, Statner, Dutta, Nathan, PC, Thousand Oaks, CA Fernando S. Alvarado, MD, FACP, MPH, TM - Infectious Disease Consultants, Altamonte Springs, FL Richard C. Prokesch, MD, FACP, FIDSA - Infectious Diseases Associates,...
Phase II and Phase III Studies
Healix regularly and actively supports Phase II and Phase III clinical trials in each of our specialty areas, including active studies in Multiple Sclerosis and Intestinal Bowel Disease.
For information on partnering with Healix on a study, please contact us.